Have a feature idea you'd love to see implemented?
Let us know!
TRVI Trevi Therapeutics Inc
Price (delayed)
$2.73
Market cap
$209.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.44
Enterprise value
$194.9M
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation
Highlights
Trevi Therapeutics's debt has decreased by 21% YoY and by 7% from the previous quarter
The EPS has shrunk by 100% YoY and by 13% QoQ
Trevi Therapeutics's net income has plunged by 66% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of TRVI
Market
Valuations
Earnings
Shares outstanding
76.87M
Market cap
$209.84M
Enterprise value
$194.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$44.34M
EBITDA
-$44.2M
Free cash flow
-$35.12M
Per share
Balance sheet
Liquidity
EPS
-$0.44
Free cash flow per share
-$0.35
Book value per share
$0.81
Revenue per share
$0
TBVPS
$0.68
Total assets
$68.91M
Total liabilities
$9.94M
Debt
$1.11M
Equity
$58.97M
Working capital
$58.21M
Debt to equity
0.02
Current ratio
7.38
Quick ratio
7.18
Net debt/EBITDA
0.34
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57.1%
Return on equity
-63.3%
Return on invested capital
-83.1%
Return on capital employed
-74.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRVI stock price
How has the Trevi Therapeutics stock price performed over time
Intraday
-1.44%
1 week
-4.55%
1 month
-18.51%
1 year
111.63%
YTD
103.73%
QTD
-18.26%
Financial performance
How have Trevi Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.22M
Net income
-$44.32M
Gross margin
N/A
Net margin
N/A
Trevi Therapeutics's net income has plunged by 66% YoY and by 14% from the previous quarter
The operating income has plunged by 52% YoY and by 12% from the previous quarter
Growth
What is Trevi Therapeutics's growth rate over time
Valuation
What is Trevi Therapeutics stock price valuation
P/E
N/A
P/B
3.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 100% YoY and by 13% QoQ
The P/B is 53% above the 5-year quarterly average of 2.2 and 16% above the last 4 quarters average of 2.9
The equity has declined by 34% year-on-year and by 11% since the previous quarter
Efficiency
How efficient is Trevi Therapeutics business performance
Trevi Therapeutics's return on invested capital has shrunk by 184% YoY and by 26% QoQ
TRVI's ROA has plunged by 133% YoY and by 24% from the previous quarter
Trevi Therapeutics's return on equity has shrunk by 133% YoY and by 27% QoQ
Dividends
What is TRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRVI.
Financial health
How did Trevi Therapeutics financials performed over time
TRVI's current ratio has dropped by 59% year-on-year and by 31% since the previous quarter
Trevi Therapeutics's quick ratio has shrunk by 58% YoY and by 30% QoQ
Trevi Therapeutics's debt is 98% less than its equity
The equity has declined by 34% year-on-year and by 11% since the previous quarter
Trevi Therapeutics's debt has decreased by 21% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.